These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2304317)

  • 1. [Calcium urolithiasis and bone change].
    Katayama Y; Umekawa T; Ishikawa Y; Kodama M; Takada M; Katoh Y; Kataoka K; Kohri K; Iguchi M; Kurita T
    Nihon Hinyokika Gakkai Zasshi; 1990 Jan; 81(1):89-95. PubMed ID: 2304317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary oxalate in summer and winter in normal subjects and in stone-forming patients with idiopathic hypercalciuria, both untreated and treated with thiazide and/or cellulose phosphate.
    Hallson PC; Kasidas GP; Rose GA
    Urol Res; 1976; 4(4):169-73. PubMed ID: 1020068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental and clinical studies on calcium lithiasis. II. Prevention of recurrent calcium stones with thiazides and allopurinol].
    Okada Y; Nonomura M; Takeuchi H; Kawamura J; Yoshida O
    Hinyokika Kiyo; 1986 Sep; 32(9):1247-57. PubMed ID: 3812144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology and therapy of hypercalciuria in patients who form recurrent stones.
    Ritz E; Schmidt-Gayk H; Möhring K
    Eur Urol; 1975; 1(3):131-3. PubMed ID: 183957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A study on the effect of the treatment for idiopathic calcium urolithiasis on the prevention of recurrences. Estimation of stone episodes and clinical effects].
    Oka T; Koide T; Sonoda T
    Nihon Hinyokika Gakkai Zasshi; 1985 Jan; 76(1):65-73. PubMed ID: 4010112
    [No Abstract]   [Full Text] [Related]  

  • 6. [Efficacy of drug prophylaxis in calcium urolithiasis].
    Yamaguchi K; Takahara M; Amakasu M; Miyauchi T; Murakami M; Ito H; Shimazaki J
    Nihon Hinyokika Gakkai Zasshi; 1986 Jul; 77(7):1177-81. PubMed ID: 3784206
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions.
    Pak CY; Heller HJ; Pearle MS; Odvina CV; Poindexter JR; Peterson RD
    J Urol; 2003 Feb; 169(2):465-9. PubMed ID: 12544288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary ionic calcium and binding sites in normocalciuric idiopathic calcium urolithiasis.
    Jacobson AL; Singhal PC; Mandin H; Hyne JB
    Invest Urol; 1979 Nov; 17(3):218-22. PubMed ID: 500320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium-loading test and bone disease in patients with urolithiasis.
    Lindergård B; Colleen S; Månsson W; Rademark C; Rogland B
    Proc Eur Dial Transplant Assoc; 1983; 20():460-5. PubMed ID: 6657669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is it necessary to systematically reduce dietary calcium intake in lithiasic patients?].
    Fuss M; Van Geel J; Pepersack T; Bergmann P; Van de Walle JC; Simon J
    Acta Urol Belg; 1988; 56(4):511-5. PubMed ID: 3207083
    [No Abstract]   [Full Text] [Related]  

  • 11. The benefits of evaluation of the patient with recurrent or multiple calcium stones.
    Peterson LJ; Hruska KA
    J Urol; 1979 Jun; 121(6):766-8. PubMed ID: 458948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A thermodynamic equilibrium model for calcium salt urolithiasis: clinical application.
    Ashby R; Györy AZ
    Exp Nephrol; 1997; 5(3):246-52. PubMed ID: 9208285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density in patients with urolithiasis. A preliminary report.
    Alhava EM; Juuti M; Karjalainen P
    Scand J Urol Nephrol; 1976; 10(2):154-6. PubMed ID: 948725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alterations in bone mineral metabolism in patients with calcium kidney stone disease and polymorphism of vitamin D receptor. Preliminary results].
    Moyano MJ; Gómez de Tejada MJ; García Lozano R; Moruno R; Ortega R; Martí V; Sánchez Palencia R; Miranda MJ; Palma A; Pérez Cano R
    Nefrologia; 2007; 27(6):694-703. PubMed ID: 18336098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density.
    Mayan H; Vered I; Mouallem M; Tzadok-Witkon M; Pauzner R; Farfel Z
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3248-54. PubMed ID: 12107233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary risk factors for recurrent calcium stone formation in Thai stone formers.
    Stitchantrakul W; Kochakarn W; Ruangraksa C; Domrongkitchaiporn S
    J Med Assoc Thai; 2007 Apr; 90(4):688-98. PubMed ID: 17487123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of metaphylaxis in calcium urolithiasis: a restriction of conventional drug therapy.
    Kocvara R; Louzenský G; Tuíková J
    Int Urol Nephrol; 1994; 26(3):269-75. PubMed ID: 7960537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thiazide diuretics and calcium metabolism: role in renal lithiasis and osteoporosis].
    Suárez Fernández C; Ruilope Urioste LM
    An Med Interna; 1996 Aug; 13(8):401-6. PubMed ID: 8983370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resorptive and absorptive hypercalciuria. Therapy with sodium cellulose phosphate or thiazides.
    Hering F; Lutzeyer W
    Eur Urol; 1979; 5(1):29-31. PubMed ID: 428408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystalluria in normal subjects and in stone formers with and without thiazide and cellulose phosphate treatment.
    Hallson PC; Rose GA
    Br J Urol; 1976; 48(7):515-24. PubMed ID: 13904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.